|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1347219536 |
| 003 |
OCoLC |
| 005 |
20231120010707.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
221012s2022 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d EBLCP
|d OCLCF
|d UKAHL
|d OCLCQ
|d CUS
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780323991742
|q (electronic bk.)
|
| 020 |
|
|
|a 0323991742
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323991735
|
| 020 |
|
|
|z 0323991734
|
| 035 |
|
|
|a (OCoLC)1347219536
|
| 050 |
|
4 |
|a RC382
|
| 082 |
0 |
4 |
|a 616.833
|2 23
|
| 245 |
0 |
0 |
|a COVID-19 and Parkinsonism /
|c Edited by K Ray Chaudhuri, Mayela Rodr�iguez-Violante, Angelo Antonini, Iro Boura.
|
| 250 |
|
|
|a First edition.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v v. 165
|
| 505 |
0 |
|
|a Intro -- Covid-19 and Parkinsonism -- Copyright -- Contents -- Contributors -- Chapter One: Parkinsonism associated with viral infection -- 1. Introduction -- 2. Epstein Barr virus -- 3. Hepatitis viruses -- 4. Human immunodeficiency virus -- 5. Herpes virus -- 6. Influenza/H1N1 -- 6.1. Encephalitis lethargica -- 7. Coxsackie virus -- 8. Flaviviruses -- 9. COVID-19 -- 10. Conclusion -- References -- Chapter Two: Covid-19, nervous system pathology, and Parkinson�s disease: Bench to bedside -- 1. Introduction -- 2. SARS-CoV-2 receptors -- 3. Neuroinflammation in post-mortem Covid-19 brain
|
| 505 |
8 |
|
|a 4. Little evidence of neuro-invasion in post-mortem Covid-19 cases -- 5. SARS-CoV-2 and parkinsonism -- 6. Peripheral pathways that may contribute to neuroinflammation -- 6.1. Olfactory pathway -- 6.2. Enteric pathways -- 6.3. Vascular pathways -- 6.4. Hypoxia and ischemia -- 7. Conclusion -- References -- Chapter Three: Prevalence and outcomes of Covid-19 in Parkinson�s disease: Acute settings and hospital -- 1. Introduction -- 2. Why should PwP be more or less susceptible to Covid-19? -- 3. Covid-19 prevalence in Parkinson�s disease -- 4. Covid-19 outcomes in Parkinson�s disease
|
| 505 |
8 |
|
|a 4.1. Hospitalization -- 4.2. Mortality -- 5. Reported modulators of Covid-19 risk in Parkinson�s disease -- 5.1. Canonical Covid-19 risk factors -- 5.2. Vitamin D -- 5.3. Age, disease severity and dementia -- 5.4. Parkinson�s disease medications -- 6. Conclusion -- References -- Chapter Four: Covid-19 and Parkinson�s disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism -- 1. Introduction -- 2. The acute effects of SARS-CoV-2 infection in people with Parkinson�s disease -- 2.1. Dopaminergic signaling during infections -- 2.2. The role of stress
|
| 505 |
8 |
|
|a 3. Parkinson�s disease and Long-COVID -- 4. Post-covid-19 cases of Parkinsonism -- 5. Conclusions -- References -- Chapter Five: Smell deficits in COVID-19 and possible links with Parkinson�s disease -- 1. Introduction -- 2. Clinical features of COVID-19 olfactory impairment -- 2.1. Individual variables influencing COVID-19 olfactory impairment -- 2.2. SARS-CoV-2 variants and their relationship with olfactory impairment -- 3. Neuropathology of COVID-19 olfactory impairment -- 4. Olfactory impairment in COVID-19 and parkinsonism -- References
|
| 505 |
8 |
|
|a Chapter Six: Spotlight on non-motor symptoms and Covid-19 -- 1. Introduction -- 2. Depression -- 3. Anxiety -- 4. Cognitive impairment -- 5. Psychosis -- 6. Delirium -- 7. Hyposmia -- 8. Gastrointestinal dysfunction -- 9. Dysautonomia -- 10. Pain -- 11. Fatigue -- 12. Sleep impairment -- 13. Conclusion -- References -- Chapter Seven: Treatment paradigms in Parkinson�s Disease and Covid-19 -- 1. Introduction -- 2. Management of PwP according to Covid-19 severity -- 3. Asymptomatic or mild Covid-19 infection -- 3.1. Anti-parkinsonian treatment: Role in Covid-19
|
| 650 |
|
0 |
|a Parkinson's disease.
|
| 650 |
|
0 |
|a COVID-19 (Disease)
|
| 650 |
|
2 |
|a COVID-19
|0 (DNLM)D000086382
|
| 650 |
|
6 |
|a Maladie de Parkinson.
|0 (CaQQLa)201-0016037
|
| 650 |
|
6 |
|a COVID-19.
|0 (CaQQLa)000313216
|
| 650 |
|
7 |
|a COVID-19 (Disease)
|2 fast
|0 (OCoLC)fst01984643
|
| 650 |
|
7 |
|a Parkinson's disease
|2 fast
|0 (OCoLC)fst01053693
|
| 700 |
1 |
|
|a Chaudhuri, K. Ray,
|e editor.
|
| 700 |
1 |
|
|a Rodr�iquez-Violante, Mayela,
|e editor.
|
| 700 |
1 |
|
|a Antonni, Angelo,
|e editor.
|
| 700 |
1 |
|
|a Boura, Iro,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t COVID-19 and Parkinsonism.
|d [Cambridge, MA] : Academic Press, 2022
|z 0323991734
|w (OCoLC)1294287964
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 165.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/165
|z Texto completo
|
